This article has been updated from a previous version.

NEW YORK, Sept. 24 (GenomeWeb News) - Merck may eventually own up to 19.9 percent of Genaissance as a  result of a license agreement between the companies in which Genaissance will use its haplotyping technology to develop a Merck antidepressant, said Genaissance CEO Kevin Rakin yesterday in a conference call. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.